Rho(D) immune globulin is a medication used to prevent Rh incompatibility in pregnant women. It is a type of injectable immunoglobulin given to pregnant women who are Rh-negative to help prevent sensitization to Rh-positive blood in the baby. Sensitization can occur when an Rh-negative mother is exposed to Rh-positive blood from her baby during childbirth, miscarriage, or other medical procedure. If sensitization occurs, the mother’s body can produce antibodies that can attack the baby’s red blood cells, leading to severe anemia. Rho(D) immune globulin helps prevent this by binding to the Rh-positive blood cells, rendering them incapable of causing sensitization.
Rho(D) immune globulin, also commonly known as RhIG or RhoGAM, is a medication used to prevent a serious condition in Rh-negative pregnancies called hemolytic disease of the newborn (HDN). Here's a breakdown of its key functions:
What it prevents:
- Hemolytic disease of the newborn (HDN): This occurs when a pregnant woman is Rh-negative and the baby is Rh-positive. In such cases, the mother's body can produce antibodies that attack the baby's red blood cells, leading to anemia, jaundice, and other complications. RhIG helps prevent this by suppressing the mother's immune response to the Rh-positive blood.
How it works:
- Suppresses immune response: RhIG contains antibodies specific to the RhD antigen, found on the surface of Rh-positive red blood cells. When introduced into the Rh-negative mother's bloodstream, these antibodies essentially "mop up" any free RhD-positive blood cells from the baby before her immune system can create its own antibodies against them. This prevents the mother's immune system from attacking the baby's red blood cells.
When is it administered:
- RhIG is typically given to Rh-negative mothers at specific points during pregnancy:
- During the first trimester (around week 28)
- After any event where the mother's blood might mix with the baby's blood, such as amniocentesis, chorionic villus sampling (CVS), or vaginal bleeding.
- Within 72 hours after delivery if the baby is Rh-positive.
Benefits:
- RhIG is a highly effective medication in preventing HDN. It has significantly reduced the risk of this serious complication in Rh-negative pregnancies.
Important considerations:
- Not a treatment: It's important to note that RhIG is a preventive measure, not a treatment for HDN. If a baby is already affected by HDN, other medical interventions will be necessary.
- Not for everyone: RhIG is only needed for Rh-negative mothers carrying an Rh-positive baby.